Objective: to study clinical, anamnestic, and laboratory parameters in children with acute and chronic urticaria. Materials and methods: fifty-five children were examined who were admitted to the pediatric department and day-time inpatient facility of the State Children’s Clinical Hospital No. 17 in Ufa in 2019. Two groups were formed: 44 patients with acute urticaria (Group 1) and 11 patients with chronic urticaria (Group 2). For the correct analysis of the hemogram and immunogram, 2 subgroups of patients with acute urticaria were formed: Group 1a – 13 children under 5 years old and Group 1b – 31 children over 5 years old. Results: acute urticaria was typical for young children (Z cor. = -2.14665; p = 0.031822). In children with acute urticaria under five years of age, there was a correlation (p < 0.05) of age with low serum JgA levels (rs = 0.806380) and the incidence of gastropathology with JgM levels (rs = 0.872872); JgG (rs = 0.763763) and the number of blood leukocytes (rs = 0.692820). In children with acute urticaria over five years of age, a correlation was found between age and concomitant gastropathology (rs = 0.421569). Patients with chronic urticaria are characterized by eosinophilia (Z cor. = -2.96741; p = 0.003003) and a pathogenetically significant increase in the CEC level (Z cor. = 1.98537; p = 0.047104). Conclusion: the revealed differences should be taken into account during the examination and management of children with urticaria.
Objective: to evaluate the clinical efficacy of targeted therapy with omalizumab in children with moderate to severe uncontrolled bronchial asthma. Materials and methods: 7 children receiving omalizumab therapy in a hospital and polyclinic of the Ufa City Children’s Clinical Hospital No. 17 were under observation. In accordance with the instructions for use, the monoclonal antibody drug omalizumab was administered subcutaneously every 2-4 weeks. The dosage of the drug was determined based on the child’s body weight and the initial level of serum IgE. The anamnesis of life and disease, the results of instrumental and laboratory research methods, the results of AST and c-AST tests were studied in all the children studied. Results: against the background of therapy with omalizumab in children, there was a significant decrease in the frequency of daytime symptoms (p=0.0179), a decrease in the frequency of night symptoms (p=0.0233), increased physical activity (p=0.0179), a decrease in the need for bronchodilators (p=0.0179), an increase in FEV1 according to spirography (p=0.0431), a decrease in the volume of basic anti-inflammatory therapy with a decrease in the dose of IGCS in 71.43% of patients (p=0.0425), a significant increase in the number of AST and c–AST test scores: before treatment 12 [10; 13] points, against the background of treatment - 23 [20; 25] points, (p=0.0277). During the follow-up period of therapy with omalizumab, no serious adverse reactions were detected. Conclusion: thus, targeted therapy using omalizumab is clinically effective in children with moderate to severe uncontrolled bronchial asthma.
Цель исследования: оценка клинической эффективности базисной противовоспалительной терапии мометазона фуроатом (Нозефрин ®) у детей с АР. Материал и методы: в исследовании приняли участие 67 пациентов в возрасте от 4 до 17 лет (49,25% (n=33) мальчиков и 50,75% (n=34) девочек), наблюдавшихся в условиях дневного стационара ГБУЗ РБ ГДКБ № 17 Уфы с ноября по декабрь 2019 г. Был проведен анализ клинико-анамнестических данных и анкет детей с персистирующим АР в периоде обострения, а также истории развития ребенка (форма 112/у) и сведений, полученных при устном опросе родителей (характер течения заболевания, тактика амбулаторного ведения пациента до обращения, особенности показателей лабораторных и инструментальных исследований). Всем детям было проведено общеклиническое, лабораторно-инструментальное обследование. На первом визите всем пациентам впервые был назначен назальный спрей мометазона фуроат (Нозефрин ®) по одной дозе (50 мкг) в каждый носовой ход 1 р./сут. Для оценки эффективности терапии проведено анкетирование перед назначением препарата, а также к исходу 1-й и 4-й нед. лечения.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.